A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder

NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the sequential-parallel comparison design (SPCD) was chosen. Two hundred and twenty subjects were randomized...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Psychiatry
Auteurs principaux: Papakostas, G. I., Johe, K., Hand, H., Drouillard, A., Russo, P., Kay, G., Kashambwa, R., Hoeppner, B., Flynn, M., Yeung, A., Martinson, M. A., Fava, M.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7303010/
https://ncbi.nlm.nih.gov/pubmed/30626911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41380-018-0334-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires